Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Steroid hormone antagonism affords vascular protection in a mouse model of vascular Ehlers-Danlos syndrome
Emily E. Juzwiak, Caitlin J. Bowen, Rhiannon Edwards, Leda Restrepo, Serena Lee, Cassie A. Parks, Anthony Zeng, Maya M. Black, Oscar E. Reyes Gaido, Emily E. Bramel, Dustin T. Shigaki, Michael A. Beer, Chiara Bellini, Harry C. Dietz, Elena Gallo MacFarlane
Emily E. Juzwiak, Caitlin J. Bowen, Rhiannon Edwards, Leda Restrepo, Serena Lee, Cassie A. Parks, Anthony Zeng, Maya M. Black, Oscar E. Reyes Gaido, Emily E. Bramel, Dustin T. Shigaki, Michael A. Beer, Chiara Bellini, Harry C. Dietz, Elena Gallo MacFarlane
View: Text | PDF
Research Article Cell biology Vascular biology

Steroid hormone antagonism affords vascular protection in a mouse model of vascular Ehlers-Danlos syndrome

  • Text
  • PDF
Abstract

Aortic dissection or rupture is a leading cause of mortality in vascular Ehlers-Danlos syndrome (VEDS), a disorder caused by mutations in the COL3A1 gene. Col3a1G938D/+ mice recapitulate features of VEDS, including high risk of aortic rupture. As in people with VEDS, aortic risk in this model accelerates at the onset of puberty, especially in males. We identify developmentally regulated gene programs associated with this vulnerability and that are targeted by treatments that mitigate aortic risk. Both genetic and pharmacological inhibition of the androgen receptor (AR) eliminated survival differences between sexes, while treatment with a dual AR and mineralocorticoid receptor (MR) antagonist provided near-complete and durable protection in both sexes. Pathways targeted by dual AR/MR inhibition, including those related to extracellular matrix (ECM) organization and cell-ECM interactions, largely overlapped with those also modulated by isolated MR antagonism. Selective targeting of MR signaling emerged as an effective therapeutic strategy in both sexes that avoids sexual side effects in males.

Authors

Emily E. Juzwiak, Caitlin J. Bowen, Rhiannon Edwards, Leda Restrepo, Serena Lee, Cassie A. Parks, Anthony Zeng, Maya M. Black, Oscar E. Reyes Gaido, Emily E. Bramel, Dustin T. Shigaki, Michael A. Beer, Chiara Bellini, Harry C. Dietz, Elena Gallo MacFarlane

×

Figure 4

AR/MR inhibition upregulates transcripts promoting ECM deposition and aerobic respiration, and downregulates transcripts related to Rho/Rac signaling and alternative mRNA splicing in multiple cell-types.

Options: View larger image (or click on image) Download as PowerPoint
AR/MR inhibition upregulates transcripts promoting ECM deposition and ae...
(A) Dot plot of cluster-defining transcripts for cluster identity. Dot color intensity indicates scaled average expression; dot size shows percentage of nuclei expressing each transcript per cluster. (B) Unsupervised clustering (Louvain resolution 0.1) identifies 4 major aortic cell populations: vascular smooth muscle cells (VSMCs), endothelial cells, fibroblasts, and immune cells, stratified by genotype (control versus VEDS). (C) Stacked bar plot showing nuclei proportion per cluster and no significant differences between treatment groups (2-way ANOVA). (D) Numbers and percentages of transcripts similarly modulated by spironolactone, finerenone, and bicalutamide or preferentially by spironolactone versus one or both other treatments (|Log2FC| ≥ 0.25, Padj ≤ 0.05). (E) Heatmap and hierarchical clustering of transcripts similarly modulated by isolated or dual AR/MR antagonism. Expression in spironolactone (Spiro)-, finerenone- (Fine-), and bicalutamide-treated (Bical-treated) samples shown relative to untreated VEDS aorta. (F) GO biological process (ribosomal transcripts excluded) and Reactome (ribosomal and mitochondrial transcripts excluded) pathway enrichment for transcripts modulated by isolated or dual AR/MR antagonism. GeneRatio = proportion of transcripts in term set; q value = FDR-adjusted P value (P ≤ 0.05). (G) Numbers and percentages of transcripts preferentially modulated by spironolactone versus finerenone, bicalutamide, or both in major aortic cell types. (H) Heatmap of transcripts from G. For E and H: red = upregulated; blue = downregulated versus untreated VEDS.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts